As in 2020, CRISPR still doesn't have an approved product -- but that could change soon. The stock has been volatile, providing investors with potential for both big gains and losses. But now that the ...

LabRoots invites you to the 3rd Annual Event in the CRISPR Virtual Event Series! This event will continue the conversation of the abilities of CRISPR-based editing, next-gen editing tools, precision ...

Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to appear soon after birth. To date, there haven’t been many reliable ...

Researchers have made an important step forward toward a long-desired goal: using the gene-editing technology CRISPR to treat cancer. In a study published in Nature, scientists recruited 16 people who ...

CRISPR has incurred nearly $500 million in losses over the past four quarters. It's burning through cash as the result of its its gene-editing therapy's slow rollout. But its development partner, ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...